Performance and Safety Follow-up of Bioabsorbable Headless Inion CompressOnTM Screws in the Fixation of Bone Fractures in Ankle, Knee and Elbow of Pediatric and Adolescent Patients

June 1, 2026 updated by: Inion Oy
The study in question is a post market clinical follow up (PMCF) study to follow up the safety and performance of bioabsorbable headless compression screw Inion CompressOn in fracture fixation of the ankle, knee and elbow of pediatric and adolescent patients. The study aims to recruit 80 patients who meet the acceptance criteria. The follow-up time for each study patient is 4 years. The study is a single center single group study which is conducted in Lighthouse Hospital at Turku University Hospital (TYKS) in Finland. The main focus of the study in terms of performance is to follow up the bone healing/ossification of operated areas. The main focus of the study in terms of safety is to evaluate the occurrence of adverse events and required revision surgeries that are or might be related to the study device.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The study in question is a post market clinical follow-up study to follow-up the safety and performance of the bioabsorbable headless Inion CompressOn Screw in fracture fixation operations of the ankle, knee and elbow of pediatric and adolescent patients. The main focus of the study in terms of performance is to follow-up the bone healing/ossification of operated areas. The main focus of the study in terms of safety is to evaluate the occurrence of adverse events and required revision surgeries that are or might be related to the study device.

The Inion CompressOn™ Screws are cannulated headless compression screws made of degradable co-polymers composed of L-lactic acid and D-lactic acid. These polymers have a long history of safe medical use and they degrade in vivo by hydrolysis into alpha-hydroxyacids that are metabolised by the body. The screws retain their initial strength up to 12 weeks after implantation and gradually lose their strength thereafter. Bioabsorption takes place within four years.

The clinical data collection acquired from this study is a requirement of the EU Notified Body as part of the admitted CE mark certification, in cases when the device is initially approved based on the clinical data of an equivalent device. In this case, the equivalent device has been Inion FreedomScrew, which is made of the same material composition and is used for the same indications. Inion CompressOn Screw has new design features such as headless design, and threading which allows compression to the fracture line. Also new sizes have been introduced.

The study recruits 80 pediatric/adolescent patients who meet the acceptance criteria and have signed the informed consent. The follow-up time for each study patient is 4 years. Each patient has 6 follow-up time points related to the study. These time points consist of:

  1. screening visit (-180-0 days before operation),
  2. operation (day 0),
  3. post-operative follow-up 1 (4-8 weeks),
  4. post-operative follow-up 2 (3 months after operation +/- 3 weeks),
  5. post-operative follow-up 3 (2 years after operation +/- 2 months)
  6. post-operative follow-up 4 (4 years after operation +/- 4 months) The first 4 time points are within standard care, the last 2 time points (post-operative follow-up 3 and post-operative follow-up 4) are scheduled for study purposes only to be able to gain performance and safety data based on adequate follow-up time.

The study is a single center single group study which is conducted in Turku University Hospital (TYKS) in Finland.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Turku, Finland, 20520
        • Recruiting
        • Turku University Hospital/Lighthouse hospital
        • Sub-Investigator:
          • Johanna Syvänen, MD
        • Contact:
        • Principal Investigator:
          • Olli Pajulo, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

1. Informed consent signed by parents or legal guardians, and assent from the child if of appropriate age and cognitive ability < 18 years 3. Suitable and in need for an operation indicated for subject device 4. Ability to give adequate input for the PROM questionnaires 5. Willingness and ability to comply with rehabilitation instructions. 6. Availability for follow-up visits.

Exclusion Criteria:

  1. Active infection
  2. Patient conditions including limited blood supply (e.g. patients with severe circulatory disorder of the lower or upper limb)
  3. Patient conditions including insufficient quality or quantity of bone (diagnosed osteoporosis, conditions causing secondary osteoporosis e.g. diabetes, rheumatism, eating disorder)
  4. Patient conditions where patient cooperation cannot be guaranteed (alcohol use, drug abuse etc.)
  5. Patients with known allergy to the implant constituents or its degradation products.
  6. Spinal and craniomaxillofacial indications.
  7. High-load bearing indications (e.g., diaphyseal fractures of long bones) unless used in conjunction with traditional rigid fixation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CompressOn group
Participants undergo a surgical fracture fixation procedure using the bioabsorbable Inion CompressOn Screw according to the device instructions for use.
Fracture fixation operation in using bioabsorbable headless Inion CompressOn Screw/s according to instructions for use

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurrence of revision surgeries
Time Frame: During 4-year follow-up
Assessment of occurrence of revision surgeries related to study device
During 4-year follow-up
Bone healing (ossification) of the fracture line(s)
Time Frame: Change from operation to 4 years
X-ray evaluation of bone healing (ossification) of the fracture line(s)
Change from operation to 4 years
Occurrence of device-related adverse events
Time Frame: During 4-year follow-up
Assessment of occurrence of adverse events (AE), that are or might be related to the study device such as non-union of bone, fixation failure, mechanical irritation and tissue reactions related to implant bioabsorption
During 4-year follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective functionality of the operated limb (Visual Analogue Scale, VAS)
Time Frame: Change from baseline to 4 years
Evaluation of subjective pain of the operated area during follow-up. 10-cm (100-mm) horizontal line used to measure pain intensity, ranging from "no pain" (0) to "worst imaginable pain" (100 mm)
Change from baseline to 4 years
Subjective functionality of the operated area (Lower Extremity Functional Scale, LEFS/Upper Extremity Functional Index, UEFI)
Time Frame: Change from baseline to 4 years

Evaluation of subjective functionality of the operated area follow-up. UEFI: The scores given to the 20 questions are added to give a highest possible score of 80. The lowest possible score is 0. A lower score indicates that the person is reporting increased difficulty with the activities as a result of their upper limb condition.

LEFS: Contains 20 questions about a person's ability to perform everyday tasks. The maximum score is 80. The lower the score the greater the disability.

Change from baseline to 4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Olli Pajulo, MD, Turku University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 29, 2026

Primary Completion (Estimated)

February 1, 2032

Study Completion (Estimated)

December 1, 2032

Study Registration Dates

First Submitted

March 11, 2026

First Submitted That Met QC Criteria

March 11, 2026

First Posted (Actual)

March 16, 2026

Study Record Updates

Last Update Posted (Actual)

June 3, 2026

Last Update Submitted That Met QC Criteria

June 1, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ankle Fractures

Clinical Trials on Fracture fixation operation

Subscribe